TY  - JOUR
UR  - https://doi.org/10.1172/jci.insight.157031
PB  - American Society for Clinical Investigation
SN  - 2379-3708
N2  - Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/?L) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-? ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination.
ID  - discovery10184137
A1  - Ogbe, A
A1  - Pace, M
A1  - Bittaye, M
A1  - Tipoe, T
A1  - Adele, S
A1  - Alagaratnam, J
A1  - Aley, PK
A1  - Ansari, MA
A1  - Bara, A
A1  - Broadhead, S
A1  - Brown, A
A1  - Brown, H
A1  - Cappuccini, F
A1  - Cinardo, P
A1  - Dejnirattisai, W
A1  - Ewer, KJ
A1  - Fok, H
A1  - Folegatti, PM
A1  - Fowler, J
A1  - Godfrey, L
A1  - Goodman, AL
A1  - Jackson, B
A1  - Jenkin, D
A1  - Jones, M
A1  - Longet, S
A1  - Makinson, RA
A1  - Marchevsky, NG
A1  - Mathew, M
A1  - Mazzella, A
A1  - Mujadidi, YF
A1  - Parolini, L
A1  - Petersen, C
A1  - Plested, E
A1  - Pollock, KM
A1  - Rajeswaran, T
A1  - Ramasamy, MN
A1  - Rhead, S
A1  - Robinson, H
A1  - Robinson, N
A1  - Sanders, H
A1  - Serrano, S
A1  - Tipton, T
A1  - Waters, A
A1  - Zacharopoulou, P
A1  - Barnes, E
A1  - Dunachie, S
A1  - Goulder, P
A1  - Klenerman, P
A1  - Screaton, GR
A1  - Winston, A
A1  - Hill, AVS
A1  - Gilbert, SC
A1  - Carroll, M
A1  - Pollard, AJ
A1  - Fidler, S
A1  - Fox, J
A1  - Lambe, T
A1  - Frater, J
KW  - AIDS/HIV
KW  -  Adaptive immunity
KW  -  COVID-19
KW  -  Cellular immune response
KW  -  T cells
KW  -  COVID-19
KW  -  ChAdOx1 nCoV-19
KW  -  HIV Infections
KW  -  Humans
KW  -  Male
KW  -  SARS-CoV-2
KW  -  Vaccination
JF  - JCI Insight
AV  - public
VL  - 7
Y1  - 2022/04/08/
TI  - Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
IS  - 7
N1  - Copyright: © 2022, Ogbe et al. This is an open access article published under the terms of the Creative CommonsAttribution 4.0 International License.
ER  -